Market Research Logo

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015’, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Bile Duct Cancer (Cholangiocarcinoma) Overview
Therapeutics Development
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
4SC AG
Agios Pharmaceuticals, Inc.
Ariad Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
AstraZeneca PLC
Bayer AG
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CellAct Pharma GmbH
Concordia Healthcare Corp.
Cornerstone Pharmaceuticals, Inc.
Delcath Systems, Inc.
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Komipharm International Co., Ltd.
Mebiopharm Co., Ltd.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Novartis AG
NuCana BioMed Limited
OncoTherapy Science, Inc.
Panacea Pharmaceuticals, Inc.
PCI Biotech AS
Pfizer Inc.
Provecs Medical GmbH
Sanofi
Senhwa Biosciences, Inc.
Spectrum Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc.
VasGene Therapeutics, Inc.
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
AG-120 - Drug Profile
ARN-5032 - Drug Profile
ARQ-087 - Drug Profile
BBI-503 - Drug Profile
BGJ-398 - Drug Profile
binimetinib - Drug Profile
cabozantinib s-malate - Drug Profile
CAP-7.1 - Drug Profile
CC-90007 - Drug Profile
CPI-613 - Drug Profile
dasatinib - Drug Profile
DKN-01 - Drug Profile
elpamotide - Drug Profile
evofosfamide - Drug Profile
gemcitabine hydrochloride - Drug Profile
Im-01 - Drug Profile
KML-001 - Drug Profile
MBPY-005 - Drug Profile
melphalan - Drug Profile
merestinib - Drug Profile
MK-2206 - Drug Profile
NUC-1031 - Drug Profile
OCVC-01 - Drug Profile
paclitaxel albumin bound - Drug Profile
PAN-622 - Drug Profile
pembrolizumab - Drug Profile
ponatinib hydrochloride - Drug Profile
porfimer sodium - Drug Profile
Recombinant Protein to Antagonize EphB4 Receptor for Oncology - Drug Profile
refametinib - Drug Profile
regorafenib - Drug Profile
resminostat - Drug Profile
RRX-001 - Drug Profile
SAR-408701 - Drug Profile
selumetinib sulfate - Drug Profile
seribantumab - Drug Profile
silmitasertib - Drug Profile
SPI-1620 - Drug Profile
sunitinib malate - Drug Profile
trametinib dimethyl sulfoxide - Drug Profile
Vaccine for Metastatic Cholangiocarcinoma - Drug Profile
vemurafenib - Drug Profile
Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca PLC, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by GlaxoSmithKline Plc, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2015
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report